Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Anita C. van Mil"'
2
Pharmacodynamics of Imipenem in Combination with β-Lactamase Inhibitor MK7655 in a Murine Thigh Model
Autor: Eleftheria Mavridou, Ria J. B. Melchers, Eric Mangin, Anita C. van Mil, Mary Motyl, Johan W. Mouton
Publikováno v: Antimicrobial Agents and Chemotherapy, 59, 790-5
Antimicrobial Agents & Chemotherapy, 59(2), 790-795. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 59, 2, pp. 790-5
MK7655 is a newly developed beta-lactamase inhibitor of class A and class C carbapenemases. Pharmacokinetics (PK) of imipenem-cilastatin (IMP/C) and MK7655 were determined for intraperitoneal doses of 4 mg/kg to 128 mg/kg of body weight. MIC and phar
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d463e95a5598897d5d1ac773a2eb071
https://doi.org/10.1128/aac.03706-14
Zobrazit plný text záznamu
3
Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice
Autor: Anita C. van Mil, Johanna Berkhout, Claudia M. Lagarde, Wright W. Nichols, Seyedmojtaba Seyedmousavi, Johan W. Mouton, Maria J. Melchers
Publikováno v: Antimicrobial Agents and Chemotherapy, 59, 4, pp. 2299-304
Antimicrobial Agents and Chemotherapy, 59, 2299-304
Antimicrobial Agents & Chemotherapy, 59(4), 2299-2304. American Society for Microbiology
Ceftazidime and the β-lactamase inhibitor avibactam constitute a new, potentially highly active combination in the battle against extended-spectrum-β-lactamase (ESBL)-producing bacteria. To determine possible clinical use, it is important to know t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b16a50fc47f8403a2b35fcbdeeebb2f
https://doi.org/10.1128/aac.04627-14
Zobrazit plný text záznamu
4
Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model
Autor: Maria J. Melchers, Anita C. van Mil, Jan den Hartigh, Claudia M. Lagarde, Johan W. Mouton
Publikováno v: Antimicrobial Agents and Chemotherapy, 61, e00267-17-e00267-17
Antimicrobial Agents and Chemotherapy, 61, 9, pp. e00267-17-e00267-17
Antimicrobial Agents and Chemotherapy, 61(9)
Antimicrobial Agents & Chemotherapy, 61(9):e00267-17. American Society for Microbiology
The lack of new antibiotics has prompted investigation of the combination of two existing agents—cefepime, a broad-spectrum cephalosporin, and tazobactam—to broaden their efficacy against extended-spectrum beta-lactamase (ESBL)-producing Enteroba
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771e13a23e3e38ef0663ca00fbaaa3c1
https://doi.org/10.1128/AAC.00267-17
Zobrazit plný text záznamu
5
Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
Autor: Virna J A Schuck, Wright W. Nichols, Johan W. Mouton, Seyedmojtaba Seyedmousavi, Anita C. van Mil, Maria J. Melchers, Claudia M. Lagarde, Johanna Berkhout
Publikováno v: Antimicrobial Agents and Chemotherapy, 60, 1, pp. 368-75
Antimicrobial Agents & Chemotherapy, 60(1), 368-375. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 60, 368-75
Avibactam is a new non-β-lactam β-lactamase inhibitor that shows promising restoration of ceftazidime activity against microorganisms producing Ambler class A extended-spectrum β-lactamases (ESBLs) and carbapenemases such as KPCs, class C β-lacta
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a03b261596dc39f3bbf4e967c415837
https://pubmed.ncbi.nlm.nih.gov/26525790
Zobrazit plný text záznamu
6
In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays
Autor: Maria J. Melchers, Wright W. Nichols, Johanna Berkhout, Johan W. Mouton, Anita C. van Mil
Publikováno v: Antimicrobial Agents and Chemotherapy, 59, 1138-44
Antimicrobial Agents and Chemotherapy, 59, 2, pp. 1138-44
Antimicrobial Agents & Chemotherapy, 59(2), 1138-1144. American Society for Microbiology
To evaluate the in vitro effects of the combination of ceftazidime and avibactam on the MICs of both compounds, checkerboard assays were performed for 81 clinical strains, including 55 Enterobacteriaceae strains (32 Klebsiella pneumoniae , 19 Escheri
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74941aab67cc7e1925e3ded014969a28
http://hdl.handle.net/2066/153132
Zobrazit plný text záznamu
7
In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae
Autor: Johan W. Mouton, Maria J. Melchers, Anita C. van Mil
Publikováno v: Antimicrobial Agents and Chemotherapy, 59, 4521-5
Antimicrobial Agents & Chemotherapy, 59(8), 4521-4525. American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 59, 8, pp. 4521-5
Ceftolozane, formally CXA-101, is a new antipseudomonal cephalosporin that is also active in vitro against Enterobacteriaceae but is vulnerable to extended-spectrum β-lactamases (ESBLs). The addition of tazobactam is intended to broaden coverage to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adef77a0c5f843fc4a5baaa83a72e96d
http://hdl.handle.net/2066/153126
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje